Today NewsXPartners Corporation (NXP) announced a multi-million dollar investment in the launch of HSL LABS.
The new company will develop clinical-quality nutritional supplement formulations specifically designed to accelerate recovery and healing following surgical procedures and injuries.
NXP’s experience in supporting nutraceutical and dietary supplement innovators worldwide underpins the launch of HSL LABS, marking a major step in promoting science-based supplements in patient care.
At the heart of HSL LABS' portfolio is the Healing Acceleration Formula, a proprietary blend designed to support tissue repair, reduce recovery time and improve patient resilience during critical pre-surgical and post-operative periods.
In contrast to most over-the-counter supplements, HSL LABS products will be available exclusively through licensed providers.
Using a carefully selected network of established physicians and surgeons will ensure that patients receive formulations within the framework of professional medical guidance.
This new approach comes at a time when the global market for surgical and injury recovery solutions is experiencing significant growth.
According to Grand View Research, the worldwide post-surgical recovery products market exceeded $12bn in 2023 and is projected to grow at a compound annual growth rate (CAGR) of more than 6% through 2030.
In parallel, the nutraceuticals sector surpassed $450bn in 2022 and is projected to reach $850bn by 2030, reflecting surging demand for clinically validated supplements and functional health products.
HSL LABS bridges these two expanding sectors, delivering evidence-driven formulations to a medical marketplace in need of innovation.
Drawing on NXP’s health communications expertise and HSL LABS’ scientific research, this initiative seeks to redefine patient-centred recovery solutions and the way advanced supplements are introduced and monitored in clinical settings.